EISSN 2148-5607

TJG IS INDEXED IN SCI-EXPANDED AND PUBMED IMPACT FACTOR: 1.4

Turkish Journal of Gastroenterology

35 414 2024

HIGHLY CITED ARTICLES

HBV and HCV are the risk factors in CCA

Tan et al.

Serum resolvin levels in irritable bowel syndrome

Karatay and Gül Utku

Microbial improvement after intervention

Qian et al.

18F-FDGPET/CT in gallbladder carcinoma

Arslan et al.

Bezoar in endoscopy

Gökbulut et al.

Effect of vitamin D on CD40L gene expression in UC

Sharifi et al.

ERCP for acute cholangitis

Khamaysi and Taha

Inborn metabolic causes of fatty liver disease

Yıldız and Sivri

Gastric and small intestinal TSA

Kiremitci et al.

COVID-19 in Hepatology and Liver transplantation

Kabaçam et al.

Submission to First Decision = 31 Days

Poster

Paritaprevir+Ritonavir+Ombitasvir+Dasabuvir±Ribavirin treatment in HCV infected chronic hemodialysis patients: A single center experience

Nilay Danis ¹ , Husnu Pullukcu ² , Tansu Yamazhan ² , Galip Ersoz ¹ , Nalan Gülsen Unal ¹ , Fulya Gunsar ¹ , Ilker Turan ¹ , Zeki Karasu ¹ , Ulus Salih Akarca ¹

Author Affiliation(s)

1.

Ege University Department of Internal Medicine Division of Gastroenterology

2.

Ege University Department of Infection Diseases

Turk J Gastroenterol 2019; 30: Supplement 18-19

DOI: 10.5152/tjg.2019.09

Keywords : HCV, Chronic renal failure, Ombitasvir - Paritaprevir – Ritonavir – Dasabuvir

Read: 2237 Downloads: 916 Published: 25 July 2019

Volume 30, Issue 1, April 2019

Previous Article

Files